Related Experiment Video
Updated: May 1, 2026

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
To B-(RAF) or not to be
Reinhard Dummer1, Simone M Goldinger1, Daniel Widmer1
1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Abstract:
The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.
Insights
Targetable mutations like BRAF and MEK are key in metastatic melanoma therapy, improving survival. Molecular heterogeneity impacts the accurate identification of these mutations, affecting treatment success.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Targetable mutations have transformed metastatic melanoma treatment.
- BRAF and MEK inhibitors significantly improve overall survival in metastatic melanoma patients.
Purpose of the Study:
- To highlight the critical role of accurate mutation identification in melanoma therapy.
- To discuss the influence of molecular heterogeneity on therapeutic outcomes.
Main Methods:
- Review of current literature on targeted therapies for metastatic melanoma.
- Analysis of the impact of molecular heterogeneity on treatment efficacy.
Main Results:
- Targeted therapies, particularly BRAF and MEK inhibitors, are effective when specific mutations are identified.
- Molecular heterogeneity can lead to challenges in identifying targetable mutations, potentially limiting therapeutic success.
Conclusions:
- Accurate identification of targetable mutations is essential for effective metastatic melanoma treatment.
- Understanding and addressing molecular heterogeneity is crucial for optimizing patient outcomes with targeted therapies.
Related Concept Videos
The Ras Gene
Ras is a...
MAPK Signaling Cascades
Framing Effects
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...

